Raptor Pharma shares should be bought on any weakness, says JMP Securities


After the FDA postponed its decision on approving Raptor's Procysbi for three months until April 30, 2013, JMP Securities doesn't believe that the delay is a reflection on the approvability of the drug. The firm thinks the drug which treats Nephropathic Cystinosis has a good chance of being approved next April 30 and it maintains an Outperform rating on the stock.

View Comments (0)